March 2023 Issue Table Of Contents

From The Editor

• Commercialization Or Bust?

Feature Articles

• Making The Right Deal For Biohaven
• Translating Nobel Prize Winning Science Into Medicine

CEO Corner

• From Science To CEO: Advice For First-Time Founders

Companies To Watch

• Hummingbird Bioscience

Industry Research

• How Well Are CDMOs Performing On Sponsors’ Most Important CDMO Selection Criteria?

Podcast Summary

• Why RNA Is Good For Business

Industry Leader

• Preparing For A Biosimilars Future

Inside The Industry

• How AI Is Driving Innovation And De-Risking R&D
• The Complicated Intersection Of AI, Life Sciences, and IP
• A Recipe For Start-Up Success With A Platform Technology
• Circumstances For Delaying, Denying, Limiting, Or Refusing An FDA Inspection
• How To Better Recruit & Retain Clinical Trial Managers
• The Neo CEO
• Why Life Sciences Boards Need More Women
• Impact Of Recent Tax Legislation On Life Sciences Companies

Leadership Lessons

• Benefit From Increasing Our Positive Intelligence

Ask The Board

• What New Value-Based Contracting Models For Cell And Gene Therapies Will Be Needed To Promote Broad Patient Access?
• Ongoing Economic Uncertainty And The Exit Of Generalist Investors From Biopharmaceuticals Continue To Put Pressure On Biopharma Company Leaders. What Advice Would You Offer?

---

2023 CDMO Leadership Awards

From The Editor

• A Real Celebration Of The Best CDMOs

Feature Article

• Gene Therapy Developer Rocket Pharma Aims High

Inside The Industry

• Regulatory Update: CDMOs And Contamination Control Strategy
• Create The Correct Checklist To Land The Best CDMO
• CDMO Performance On Service Provider Selection Criteria
• Make The Service Agreement Work For You And Your CDMO
• Outsourcing Strategies For Maximizing Drug Exclusivity

CDMO Leadership Awards Winners